Nutritional implications of cephalic phase gastrointestinal responses.
Palatable cephalic stimuli induce a simultaneous activation of gastrointestinal motility, gastric acid and pancreatic enzyme secretion, as well as, release of the gastrointestinal hormones gastrin and pancreatic polypeptide. Cholinergic neural input is the dominant mediator of these responses with cholecystokinin and gastrin acting as additional stimulatory modulators. Central cholinergic circuits, neuropeptide Y, and thyrotropin releasing hormone are candidate central stimulators of the cephalic phase. There are good arguments for glucagon-like peptide-1 and peptide YY to be physiological inhibitors of cephalic-phase responses with these peptides being released in the intestinal phase of digestion and putatively contributing to termination of the cephalically stimulated pattern. Cephalic-phase responses are used clinically as diagnostic tests to assess completeness of selective proximal vagotomy and to explore autonomic neuropathy. Pancreatic polypeptide secretion with sham feeding is an appropriate test of abdominal vagal function. Cephalically stimulated motor and secretory activity contribute greater than 50% of overall postprandial responses. Pharmacological inhibition of cephalic-vagal stimulation, resulting in reduced food intake, may be a novel approach to obesity management. Glucagon-like peptide-1 is a particular candidate because it inhibits the cephalic phase of digestion, diminishes food intake, and reduces the glycemic excursion after a meal by retarding gastric emptying, stimulating insulin and lowering glucagon release.
Katschinski
M
M
Department of Gastroenterology and Endocrinology, Philipps-University Marburg, Baldingerstr. 1, Marburg, 35033, Germany.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D004063:Digestion; D004068:Digestive System Physiological Phenomena; D004435:Eating / Q000502:physiology* / Q000523:psychology; D005744:Gastric Acid / Q000378:metabolism; D005768:Gastrointestinal Hormones / Q000378:metabolism / Q000502:physiology; D006727:Hormone Antagonists / Q000494:pharmacology; D006801:Humans; D009046:Motor Neurons / Q000187:drug effects; D009747:Nutritional Physiological Phenomena; D010276:Parasympatholytics / Q000494:pharmacology; D011377:Proglumide / Q000031:analogs & derivatives / Q000494:pharmacology
D005768:Gastrointestinal Hormones; D006727:Hormone Antagonists; D010276:Parasympatholytics; C053737:loxiglumide; D001285:Atropine; D011377:Proglumide